Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection

Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection

Background/Purpose: Hepatitis B virus (HBV) reactivation may occur in >10% of patients with lymphoma and resolved HBV infection who undergo rituximab-containing chemotherapy. Preventive strategies may have marked impact on resource allocation in HBV endemic areas. This study aims to compare the c...

Full description

Bibliographic Details
Main Authors: Hsiao-Hui Tsou, Hung-Chih Yang, Chin-Fu Hsiao, Chao A. Hsiung, Tsang-Wu Liu, Mei-Hsing Chuang, Hsiao-Yu Wu, Ya-Ting Hsu, Chiung-Wen Tsui, Pei-Jer Chen, Ann-Lii Cheng, Chiun Hsu
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Journal of the Formosan Medical Association
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664619301391

Internet

http://www.sciencedirect.com/science/article/pii/S0929664619301391

Similar Items